Personalis Debt to Equity Ratio 2018-2026 | PSNL
Current and historical debt to equity ratio values for Personalis (PSNL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Personalis debt/equity for the three months ending March 31, 2026 was 0.00.
| Personalis Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $0.07B | $0.26B | 0.28 |
| 2025-12-31 | $0.07B | $0.26B | 0.28 |
| 2025-09-30 | $0.07B | $0.17B | 0.42 |
| 2025-06-30 | $0.07B | $0.19B | 0.36 |
| 2025-03-31 | $0.07B | $0.21B | 0.32 |
| 2024-12-31 | $0.07B | $0.20B | 0.33 |
| 2024-09-30 | $0.07B | $0.17B | 0.44 |
| 2024-06-30 | $0.07B | $0.11B | 0.65 |
| 2024-03-31 | $0.08B | $0.12B | 0.62 |
| 2023-12-31 | $0.10B | $0.13B | 0.74 |
| 2023-09-30 | $0.08B | $0.15B | 0.50 |
| 2023-06-30 | $0.07B | $0.18B | 0.41 |
| 2023-03-31 | $0.08B | $0.19B | 0.41 |
| 2022-12-31 | $0.08B | $0.22B | 0.34 |
| 2022-09-30 | $0.08B | $0.24B | 0.31 |
| 2022-06-30 | $0.09B | $0.27B | 0.35 |
| 2022-03-31 | $0.09B | $0.29B | 0.33 |
| 2021-12-31 | $0.09B | $0.31B | 0.28 |
| 2021-09-30 | $0.08B | $0.33B | 0.25 |
| 2021-06-30 | $0.05B | $0.34B | 0.13 |
| 2021-03-31 | $0.05B | $0.35B | 0.14 |
| 2020-12-31 | $0.05B | $0.20B | 0.26 |
| 2020-09-30 | $0.05B | $0.20B | 0.22 |
| 2020-06-30 | $0.05B | $0.09B | 0.56 |
| 2020-03-31 | $0.05B | $0.10B | 0.53 |
| 2019-12-31 | $0.05B | $0.11B | 0.47 |
| 2019-09-30 | $0.05B | $0.11B | 0.43 |
| 2019-06-30 | $0.08B | $0.12B | 0.64 |
| 2019-03-31 | $0.00B | $0.00B | 0.00 |
| 2018-12-31 | $0.00B | 0.00 | |
| 2018-09-30 | $0.00B | $0.00B | 0.00 |
| 2018-06-30 | $0.00B | $0.00B | 0.00 |
| 2017-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |